Abstracts Archive - Page 2312 of 2425 - ACR Meeting Abstracts

Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Maria Victoria Hernández¹, Miguel A. Descalzo², Juan D. Cañete¹, Raimon Sanmarti³ and BIOBADASER Study Group⁴, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Research Unit. Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Diane Lacaille¹, Michal Abrahamowicz², Eric C. Sayre³ and John Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
Abstract Number: 1643 • 2012 ACR/ARHP Annual Meeting
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Megan E. B. Clowse¹, Douglas C. Wolf², Christian Stach³, Gordana Kosutic⁴, Susan Williams⁴, Ido Terpstra⁵ and Uma Mahadevan⁶, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Brussels, Belgium, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Pre-clinical…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…
Abstract Number: 1645 • 2012 ACR/ARHP Annual Meeting
Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases
Dilrukshie Cooray¹, Saleem A. Waraich², Andrew Phan¹, Rosalinda C. Moran¹ and George A. Karpouzas¹, ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Placentia, CA
Background/Purpose: Patients with rheumatic diseases (RD) are typically treated with conventional and /or biologic disease modifying anti-rheumatic drugs (DMARD's) including tumor necrosis factor inhibitors (TNFi). …
Abstract Number: 1646 • 2012 ACR/ARHP Annual Meeting
The Mechanism of Umbilical Cord Mesenchymal Stem Cells in the Upregulation of Regulatory T Cells by TGF-β1 in Systemic Lupus Erythematosus
Lingyun Sun¹, Dandan Wang², Lin Lu² and Xia Li², ¹the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown immunoregulation on various immune cells. The aim of this study is to investigate the…
Abstract Number: 1647 • 2012 ACR/ARHP Annual Meeting
Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids
Peter M. Izmirly¹, Sara Sahl¹, Amit Saxena², Nathalie Costedoat-Chalumeau³, Jean-Charles Piette⁴, Munther A. Khamashta⁵, Cecilia Pisoni⁶, Deborah Friedman⁷ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Section of Rheumatology and Immunology, Centro de Educación, CEMIC, CABA, Argentina, ⁷Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Life-threatening cardiac manifestations of neonatal lupus (cardiac-NL) include complete block, endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM), all supportive of intense fibrosis at the…
Abstract Number: 1648 • 2012 ACR/ARHP Annual Meeting
Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss
Michelle Petri¹, Anil Mankee², Ehtisham Akhter², Hong Fang¹ and Laurence S. Magder³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Multiple factors, including proteinuria, antiphospholipid syndrome, thrombocytopenia and hypertension, are predictive of pregnancy loss in SLE. In the PROMISSE study of mediators of pregnancy…
Abstract Number: 1649 • 2012 ACR/ARHP Annual Meeting
French Cohort Study of 141 Cases of Autoimmune Congenital Heart Block
Kateri Levesque¹, Alice Maltret², Mohamed Hamidou³, Moez Jallouli⁴, Jean Loup Pennaforte⁵, Pauline Orquevaux⁵, Jean-Charles Piette⁶, Zahir Amoura⁴, Francois Barriere⁷, Jérome Le Bidois², Laurent Fermont², Laurence Cohen⁸, Olivier Meyer⁹, Olivier Fain¹⁰, Arnaud Theulin¹¹, Hugues Lucron¹², Francois Sassolas¹³, Holly Bezanahary¹⁴, Gaëlle Guettrot-Imbert¹⁵, Pascal Seve¹⁶, Elizabeth Diot¹⁷, Nathalie Morel¹, Christophe Deligny¹⁸, Elisabeth Villain² and Nathalie Costedoat-Chalumeau¹⁹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ³Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁴Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁵Hu Robert Debre, CHU Reims, Reims, France, ⁶Hospital Pitie, Paris, ⁷Pediatry, CHU Nantes, Nantes, France, ⁸Cardiology, Institut Jacques Cartier, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, Bondy, France, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Cardiology, CHU Fort-de-France, Fort de France, Martinique, ¹³Cardiology, CHU Lyon, Lyon, France, ¹⁴Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁵Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Internal medicine, CHU Lyon, Lyon, France, ¹⁷Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ¹⁸Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹⁹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Cardiac neonatal lupus manifestations mainly include congenital heart block (CHB), endocardial fibroelastosis and dilated cardiomyopathy. We report the preliminary results of the French registry…
Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting
Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy
Jill P. Buyon¹, Aanam Aslam², Marta M. Guerra², Michael D. Lockshin³, Carl A. Laskin⁴, Ware Branch⁵, Lisa R. Sammaritano⁶, Michelle Petri⁷, Joan T. Merrill⁸, Allen D. Sawitzke⁹ and Jane E. Salmon⁶, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting
Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort
Ben Parker¹, Murray B. Urowitz², Dafna D. Gladman³, Mark Lunt⁴, Ian N. Bruce⁵ and Systemic Lupus International Collaborating Clinic (SLICC)⁶, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Toronto
Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khoutra⁴, Olivier Aumaitre⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puechal¹⁴, Pierre-Louis Carron¹⁵, Pierre yves Hatron¹⁶, Nicolas Limal¹⁷, Mohamed Hamidou¹⁸, Maize Ducret¹⁹, Florence Vende²⁰, Elisa Pasqualoni²¹, Bernard Bonnotte²², Philippe Ravaud²³, Luc Mouthon²⁴ and French Vasculitis Study Group (FVSG)²⁵, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ⁵Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Centre Hospitalier, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Hôpital Cochin, Paris, France, ¹⁵Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁶Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹⁷Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁸Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁹Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, ²⁰Nephrology, Hôpital Bicbat, APHP, Paris, France, ²¹Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, ²²Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²⁴Internal Medicine, Hopital Cochin, Paris, France, ²⁵Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
Abstract Number: 1653 • 2012 ACR/ARHP Annual Meeting
Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy
Jason Springer¹, Benjamin Nutter², Carol A. Langford³, Gary S. Hoffman⁴ and Alexandra Villa-Forte⁵, ¹Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ³Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Disease remission can be successfully achieved in the majority of patients (pts) with Granulomatosis with polyangiitis (Wegener’s) (GPA). After remission (rem) is achieved continued…
Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting
Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Eli Miloslavsky¹, Ulrich Specks², John H. Stone³ and RAVE/ITN Research Group⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Bethesda, MD
Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting
An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)
Carol A. Langford¹, David Cuthbertson², Gary S. Hoffman³, Jeffrey Krischer⁴, Carol McAlear⁵, Paul A. Monach⁶, Philip Seo⁷, Ulrich Specks⁸, Steven R. Ytterberg⁹, Peter A. Merkel⁵ and for the Vasculitis Clinical Research Consortium⁵, ¹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁴University of South Florida, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁸Mayo Clinic, Rochester, MN, ⁹Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].